Market Risers: G4S plc, Ilika plc, ImmuPharma PLC

Ilika plc

Shares of G4S plc with ticker code: LON:GFS has gained 1.08% or 3.1 points throughout the session so far. Buyers have remained optimistic throughout the session. The high for the period has reached 292.8 while the low for the session was 288.4. The total volume of shares exchanged through this period comes to 1,245,618 whilst the average number of shares exchanged is 4,122,308. A 52 week share price high is 342.6 some 54.6 points in difference on the previous days close and a 52 week low being 244.9 which is a difference of 43.1 points. G4S plc now has a 20 SMA of 278.96 and now the 50 day moving average now at 265.28. The market capitalisation currently stands at £4,516.69m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for G4S plc being recorded at Friday, January 19, 2018 at 1:21:31 PM GMT with the stock price trading at 291.1 GBX.

 

 

The stock price for Ilika plc EPIC code: LON:IKA has stepped up 24.44% or 5.5 points during today’s session so far. Investors are a positive bunch during the session. The periods high has reached 28 meanwhile the session low reached 22. The total volume traded so far comes to 182,609 while the daily average number of shares exchanged is 77,320. The stock 52 week high is 53 which comes in at 30.5 points different to the previous business close and a 52 week low sitting at 18 is a variance of 4.5 points. Market capitalisation is now £24.70m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Ilika plc being recorded at Friday, January 19, 2018 at 1:14:32 PM GMT with the stock price trading at 28 GBX.

 

 

Shares of ImmuPharma PLC with ticker code: LON:IMM has climbed 5.64% or 9.5 points in today’s trading session so far. Investors have remained positive during this period. The periods high figure was 184.97 while the low for the session was 171.51. Volume total for shares traded during this period was 802,887 whilst the average number of shares exchanged is 519,298. The 52 week high for the share price is 193.74 which comes in at 25.24 points different to the previous business close and a 52 week low sitting at 44 which is a variance of 124.5 points. ImmuPharma PLC has a 20 day moving average of 173.87 and now a 50 day simple moving average now of 146.59. The current market capitalisation is £230.81m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for ImmuPharma PLC being recorded at Friday, January 19, 2018 at 12:59:22 PM GMT with the stock price trading at 178 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Ilika CEO on Goliath scale-up, UKBIC trials & further grants (LON:IKA)

Ilika plc's CEO Graeme Purdy discusses the scale-up of Goliath battery manufacturing at UKBIC, leveraging government grants and future opportunities.

Ilika Plc Scaling Solid-State Battery Tech with Game-Changing Manufacturing Breakthrough (Video)

Discover how Ilika Plc is advancing solid-state battery tech. CEO Graeme Purdy discusses the breakthrough with Goliath batteries for the EV market.

Ilika’s Goliath achieves manufacturing scale-up with UKBIC collaboration

Ilika plc (LON:IKA) advances its Goliath solid-state battery commercialization through successful UK Battery Industrialisation Centre collaboration.

UK Sustainable Investments Latest News

Explore the latest advancements in the UK's sustainable investments, from renewable energy breakthroughs to green technology funding, paving the path to a greener future.

Ilika: Pioneering Solid-State Battery Advancements (LON:IKA)

Ilika plc (LON:IKA) CEO Graeme Purdy discusses exciting Stereax and Goliath milestones, including US commissioning and customer engagement strategies.

Inside Ilika plc, The Road to Commercialising Revolutionary Battery Tech with Dr Tom McColm (Video)

Explore insights from Dr. Tom McColm on Ilika plc’s advances in solid-state batteries and their journey towards commercial success in medtech and EV markets.

Search

Search